Table 1.
Outcome | Study designs | Representative studies |
Main Findings |
---|---|---|---|
De novo HCC | |||
DAA with SVR vs. Treatment failure |
(8, 9, 11) | Lower risk of HCC in patients with SVR after DAAs compared to patients without SVR |
|
DAA vs. No treatment |
(10, 12) | Lower risk of HCC in patients receiving DAAs compared to patients remaining untreated |
|
DAA vs. IFN |
(7, 9, 12) |
No difference in risk of HCC with DAA treatment compared to IFN treatment |
|
Recurrent HCC | |||
DAA treated patients only |
(13, 15) | Higher than expected proportion of patients with recurrent HCC after starting DAA therapy |
|
DAA treated vs. control |
(38–41) | No difference in risk of recurrent HCC with DAA treatment compared to no treatment or IFN- treated patients |